A5082333467- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Health Systems, Economic Evaluations, Quality of Life
- Rheumatoid Arthritis Research and Therapies
- Delphi Technique in Research
- Patient-Provider Communication in Healthcare
- Mental Health and Patient Involvement
- Clinical practice guidelines implementation
- Interprofessional Education and Collaboration
- Adolescent and Pediatric Healthcare
- Pharmaceutical Practices and Patient Outcomes
- Innovations in Medical Education
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Lymphoma Diagnosis and Treatment
- Primary Care and Health Outcomes
- Chronic Disease Management Strategies
- Healthcare Systems and Technology
- Medication Adherence and Compliance
- Clinical Reasoning and Diagnostic Skills
- Musculoskeletal Disorders and Rehabilitation
- Interpreting and Communication in Healthcare
University Health Network
2016-2024
Toronto Western Hospital
2015-2024
University of Toronto
2014-2023
Children's Hospital of Eastern Ontario
2017-2019
Institute for Work & Health
2019
Ottawa Hospital
2017-2019
University of Ottawa
2017-2019
University of British Columbia
2017-2019
Oregon Health & Science University
2017-2019
The University of Sydney
2019
Objective To update the 2009 Group for Research and Assessment of Psoriasis Psoriatic Arthritis (GRAPPA) treatment recommendations spectrum manifestations affecting patients with psoriatic arthritis (PsA). Methods GRAPPA rheumatologists, dermatologists, PsA drafted overarching principles management PsA, based on consensus achieved at face‐to‐face meetings via online surveys. We conducted literature reviews regarding key domains (arthritis, spondylitis, enthesitis, dactylitis, skin disease,...
Objective. To include the patient perspective in accordance with Outcome Measures Rheumatology (OMERACT) Filter 2.0 updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). Methods. At OMERACT 2016, research conducted to update PsA was presented discussed breakout groups. The voted on endorsed by participants. Results. We a systematic literature review of domains measured RCT LOS, identified 24 domains. focus...
To estimate the prevalence and incidence of psoriasis psoriatic arthritis (PsA) over time in Ontario, Canada.We performed a population-based study Ontario health administrative data, using validated case definitions for PsA. We computed crude age- sex-standardized cumulative from 2000 to 2015.Among 10,774,802 individuals ages ≥20 years residing 2015, we identified 273,238 patients with 18,655 PsA, equating estimates 2.54% 0.17%, respectively. Correcting imperfect sensitivity specificity...
A meeting was convened by the Group for Research and Assessment of Psoriasis Psoriatic Arthritis (GRAPPA) Outcome Measures in Rheumatology (OMERACT) to further development consensus among physicians patients regarding composite disease activity measures targets psoriatic arthritis (PsA).Prior meeting, completed surveys on outcome measures. 26 rheumatologists, dermatologists, patient research partners reviewed evidence potential treatment plus results surveys. The consisted plenary...
The Group for Research and Assessment of Psoriasis Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis core domain set, a set disease features that should be measured all clinical trials. At GRAPPA annual meeting July 2016, PsA presented endorsed by 90% participants at OMERACT May drafted roadmap development outcome measurement set. In this manuscript, we review process ongoing proposed...
The objectives of this systematic literature review (SLR) were to identify domains and outcome measures used in psoriatic arthritis (PsA) studies the past 5 years, compare measurement Outcome Measures Rheumatology (OMERACT) 2006 PsA Core Domain Set published 2010-2015 vs those 2006-2010. We performed a search two databases, PubMed Embase, randomised controlled trials (RCTs) PsA. also identified longitudinal observational (LOS). Three patient research partners provided input into study...
The GRAPPA-OMERACT psoriatic arthritis (PsA) working group is in the process of updating PsA core domain set to improve and standardize measurement outcomes. Work streams comprise literature reviews domains outcome instruments, an international qualitative research project with patients generate important patients, instrument assessment, conduct consensus panels physicians, evidence-based selection instruments. Patient partners are involved each projects. will present findings seek...
The aim of this Outcome Measures in Rheumatology (OMERACT) Working Group was to determine the core set outcome domains and subdomains for measuring effectiveness shared decision-making (SDM) interventions rheumatology clinical trials.Following OMERACT Filter 2.0, based on a previous literature review SDM nominal group process at 2014, (1) an online Delphi survey conducted gather feedback draft refine its subdomains, (2) workshop held 2016 meeting gain consensus set.A total 170 participants...
Objectives. We assessed the accuracy of case definition algorithms for psoriasis and psoriatic arthritis (PsA) in health administrative data used primary care electronic medical records (EMR) to describe disease treatment characteristics these patients. Methods. randomly sampled 30,424 adult Ontario residents from Electronic Medical Record Primary Care database identified 2215 patients with any possible disease–related terms their EMR. The relevant patient were chart abstracted confirm...
Objective. The Outcome Measures in Rheumatology (OMERACT) Shared Decision Making (SDM) Working Group aims to determine the core outcome domain set for measuring effectiveness of SDM interventions rheumatology trials. Methods. A white paper was developed clarify draft set. It then used prepare interviews investigate reasons lack consensus on it and suggest further improvements. Results. OMERACT scientists/clinicians (n = 13) patients 10) suggested limiting domains, removing process clarifying...
For the first time, 8 patients with psoriatic arthritis (PsA) participated as full delegates at 2013 Annual Meeting of Group for Research and Assessment Psoriasis Psoriatic Arthritis (GRAPPA). Patients were invited to provide their perspective different sessions conference program. Before conference, patient had a separate meeting familiarize themselves program gain better understanding vision objectives GRAPPA. During group discussed options increased involvement in research projects....
Objective Information about the prediagnosis period in psoriatic arthritis (PsA) is limited. The present study was undertaken to compare health care utilization related musculoskeletal issues during a 5‐year prior diagnosis of PsA versus that subjects with no inflammatory within primary setting. Methods We conducted population‐based, matched cohort using electronic medical records and administrative data Ontario, Canada. Age‐ sex‐matched cohorts patients comparators from same family...
Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity. The Outcome Measures in Rheumatology (OMERACT) Equity Working Group aims to determine whether address equity issues within the core outcome sets of domains instruments.We surveyed current previous OMERACT meeting attendees members Campbell Cochrane Filter 2.0 Core Sets assess appropriateness domains,...